Mucosal melanoma is a rare and aggressive form of melanoma that develops in the thin, moist lining (mucosa) of body cavities rather than on the skin. It accounts for roughly 1.3% of all melanoma cases and behaves very differently from the more common cutaneous type, both genetically and clinically. Because it grows in hidden locations like the nasal passages, mouth, rectum, and genital tract, it is often caught at a later stage and carries a significantly worse prognosis.
Where Mucosal Melanoma Develops
Melanocytes, the pigment-producing cells most people associate with skin, also exist in the mucous membranes that line the respiratory, gastrointestinal, and urogenital tracts. When these melanocytes turn cancerous, the result is mucosal melanoma. The most common sites break down into three broad regions.
Head and neck: This is the most frequent location, representing 31% to 51% of all mucosal melanomas. Within the head and neck, tumors most often appear in the nasal cavity and paranasal sinuses, followed by the oral cavity and, rarely, the throat.
Anorectal region: About 31% of gastrointestinal mucosal melanomas arise in the anal canal and another 22% in the rectum. The oropharyngeal area accounts for roughly 33%. Other gastrointestinal sites like the esophagus, stomach, and small bowel are extremely rare origins.
Female genital tract: Vulvar melanoma makes up about 77% of genital mucosal melanomas, vaginal melanoma about 20%, and cervical melanoma is the least common. Melanoma can also arise in the urethra and urinary bladder, though this is uncommon.
How It Differs From Skin Melanoma
The most important distinction is that UV radiation, the primary driver of skin melanoma, does not play a meaningful role in mucosal melanoma. Mucosal surfaces simply aren’t exposed to sunlight. This fundamental difference extends to the tumor’s genetics. About 50% of cutaneous melanomas carry a BRAF mutation, the target of several effective drugs. In mucosal melanoma, BRAF mutations appear in only about 8% of cases, and when they do occur, 37% sit on unusual locations within the gene that don’t respond as well to standard targeted therapies.
NRAS mutations show up in roughly 12% of mucosal melanomas, compared to higher rates in skin melanoma, and the specific mutation locations differ as well. A separate genetic change involving a protein called KIT is found in 10% to 22% of mucosal melanomas, which is uncommon in cutaneous melanoma. These genetic differences matter because they limit which targeted treatments are effective.
The staging system also reflects how different mucosal melanoma is. The American Joint Committee on Cancer classifies any mucosal melanoma confined to the mucosa as at least stage III, skipping stages I and II entirely. This isn’t an arbitrary choice. It reflects the reality that even localized mucosal melanoma behaves like advanced disease, with high rates of local recurrence and a tendency to invade blood vessels early.
Symptoms by Location
Because mucosal melanoma hides inside body cavities, symptoms tend to be vague and easy to dismiss as minor problems. The specific warning signs depend on where the tumor is growing.
- Nasal and sinus: Repeated nosebleeds from one nostril, persistent congestion or a feeling that something is blocking the nose, and a continuous runny nose.
- Oral cavity: A lump on the tongue or inside the mouth that doesn’t resolve, a sore that won’t heal, mouth pain, unexplained bleeding, or dentures that suddenly fit poorly.
- Throat: Hoarseness and difficulty swallowing, though this location is the least common.
- Anorectal: Bleeding during bowel movements, a mass near the anus, changes in bowel habits, or pain in the rectal area.
- Vulvar or vaginal: Unusual bleeding or discharge, a visible pigmented or non-pigmented mass, itching, or pain.
None of these symptoms are unique to melanoma, which is a major reason diagnosis is frequently delayed. Many patients are initially treated for more common conditions like nasal polyps, hemorrhoids, or infections before a biopsy reveals the true cause.
Risk Factors
Without UV exposure as a trigger, the causes of mucosal melanoma remain less clear than for skin melanoma. Some identified risk factors include fair skin that burns or freckles easily, naturally blonde or red hair, blue or green eyes, and a family history of melanoma. Exposure to certain industrial chemicals, particularly those used in the textile and leather industries, has also been linked to increased risk. The disease affects women more often than men, with incidence rates of 2.8 per million in women compared to 1.5 per million in men, likely reflecting the contribution of vulvovaginal cases. Unlike cutaneous melanoma, whose incidence has been climbing steadily for decades, the rate of mucosal melanoma has remained essentially flat.
Diagnosis
Tissue biopsy remains the definitive way to confirm mucosal melanoma. In practice, how that biopsy happens depends on the tumor’s location. Nasal and sinus tumors are typically found during endoscopy, anorectal tumors during colonoscopy or examination, and oral tumors during dental or medical exams. Imaging with CT or MRI helps determine how far the tumor extends into surrounding tissue, which is critical for surgical planning.
Newer non-invasive imaging techniques are being explored for mucosal sites where biopsy can be particularly difficult or damaging. High-resolution skin imaging devices originally designed for skin lesions have been adapted to perform “virtual biopsies” of mucosal surfaces, producing detailed images of the top layers of tissue and helping distinguish benign from malignant growths without cutting.
Treatment
Surgery is the primary treatment when the tumor can be removed. The goal is a wide local excision, taking the melanoma along with a margin of healthy tissue around it. In the head and neck, achieving clear margins is often challenging because of the complex anatomy. Nearby lymph nodes may be checked during the same procedure using sentinel node biopsy, and if cancer is found, additional nodes may be removed.
Immunotherapy plays a growing role, especially for tumors that can’t be fully removed or have spread. However, mucosal melanoma responds less well to these treatments than skin melanoma does. For the immunotherapy drug pembrolizumab, the response rate in mucosal melanoma is about 19%, compared to 33% for cutaneous melanoma. Nivolumab alone produces a similar 23% response rate. Combining two immunotherapy drugs, nivolumab and ipilimumab, pushes the response rate to 37% in mucosal melanoma, though that still trails the 60% seen in skin melanoma.
Targeted therapy options are limited because the genetic mutations these drugs attack are far less common in mucosal melanoma. The small percentage of patients whose tumors carry KIT mutations may benefit from drugs that target that protein, and the roughly 8% with BRAF mutations may respond to BRAF-targeted therapy, though the unusual mutation patterns in mucosal melanoma can reduce effectiveness. Median overall survival for patients treated with pembrolizumab has been reported at 11.3 months, underscoring the challenge this disease presents even with modern treatments.
Why Prognosis Is Worse
Several factors converge to make mucosal melanoma more dangerous than its cutaneous counterpart. The hidden locations mean tumors grow undetected for longer, often reaching significant size before causing noticeable symptoms. The rich blood supply of mucosal tissues gives cancer cells easier access to the bloodstream, enabling earlier spread. The genetic profile of these tumors makes them less responsive to the targeted therapies and immunotherapies that have transformed outcomes for skin melanoma. And the complex anatomy of sites like the nasal sinuses or rectum makes achieving complete surgical removal more difficult, leading to higher rates of local recurrence. All of these factors combine to explain why even the staging system treats mucosal melanoma as advanced disease from the start.